Maze Therapeutics Inc. reported its financial results for the first quarter of 2025, showing a cash and cash equivalents position of $294.4 million as of March 31, 2025, an increase from $196.8 million as of December 31, 2024. The company expects this cash position to fund its operations into the second half of 2027. Research and development expenses rose to $27.6 million in Q1 2025 from $21.9 million in the same period of 2024. This increase was mainly due to higher clinical trial expenses for MZE829 and MZE782, as well as personnel-related expenses. General and administrative expenses also increased, reaching $7.8 million in Q1 2025 compared to $6.1 million in Q1 2024, attributed to higher personnel and professional services fees. Maze Therapeutics reported a net loss of $32.8 million for the first quarter of 2025, slightly higher than the $32.5 million loss reported in the same quarter of the previous year. The company is actively progressing with its clinical programs, including the Phase 2 HORIZON trial of MZE829 for APOL1 Kidney Disease, with initial data expected in Q1 2026. Additionally, the Phase 1 trial of MZE782 is ongoing, with initial data anticipated in Q3 2025 to support Phase 2 trials in chronic kidney disease (CKD) and phenylketonuria (PKU). Maze's strong balance sheet positions it well to advance its pipeline and mission.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.